Passive Transfer of A Germline-like Neutralizing Human Monoclonal Antibody Protects Transgenic Mice Against Lethal Middle East Respiratory Syndrome Coronavirus Infection

Anurodh Shankar Agrawal, Tianlei Ying, Xinrong Tao, Tania Garron, Abdullah Algaissi, Yanping Wang, Lili Wang, Bihung Peng, Shibo Jiang, Dimiter S. Dimitrov, Chien-Te Tseng

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Middle East Respiratory Syndrome coronavirus (MERS-CoV) has repeatedly caused outbreaks in the Arabian Peninsula. To date, no approved medical countermeasures (MCM) are available to combat MERS-CoV infections. Several neutralizing human monoclonal antibodies (mAbs), including m336, a germline-like human mAb, have been chosen as promising MCM for MERS-CoV. However, their clinical development has been hindered by the lack of a robust animal model that recapitulate the morbidity and mortality of human infections. We assessed the prophylactic and therapeutic efficacy of m336 by using well-characterized transgenic mice shown to be highly sensitive to MERS-CoV infection and disease. We found that mice treated with m336 prior to or post lethal MERS-CoV challenging were fully protected, compared to control mice which sufferered from profound weight loss and uniform death within days after infection. Taken together, these results support further development of m336 and other human monoclonal antibodies as potential therapeutics for MERS-CoV infection.

Original languageEnglish (US)
Article number31629
JournalScientific Reports
Volume6
DOIs
StatePublished - Aug 19 2016

Fingerprint

Coronavirus Infections
Transgenic Mice
Monoclonal Antibodies
Infection
Disease Outbreaks
Middle East Respiratory Syndrome Coronavirus
Weight Loss
Animal Models
Morbidity
Mortality
Therapeutics

ASJC Scopus subject areas

  • General

Cite this

Passive Transfer of A Germline-like Neutralizing Human Monoclonal Antibody Protects Transgenic Mice Against Lethal Middle East Respiratory Syndrome Coronavirus Infection. / Agrawal, Anurodh Shankar; Ying, Tianlei; Tao, Xinrong; Garron, Tania; Algaissi, Abdullah; Wang, Yanping; Wang, Lili; Peng, Bihung; Jiang, Shibo; Dimitrov, Dimiter S.; Tseng, Chien-Te.

In: Scientific Reports, Vol. 6, 31629, 19.08.2016.

Research output: Contribution to journalArticle

Agrawal, Anurodh Shankar ; Ying, Tianlei ; Tao, Xinrong ; Garron, Tania ; Algaissi, Abdullah ; Wang, Yanping ; Wang, Lili ; Peng, Bihung ; Jiang, Shibo ; Dimitrov, Dimiter S. ; Tseng, Chien-Te. / Passive Transfer of A Germline-like Neutralizing Human Monoclonal Antibody Protects Transgenic Mice Against Lethal Middle East Respiratory Syndrome Coronavirus Infection. In: Scientific Reports. 2016 ; Vol. 6.
@article{e63ccbd0685c4df8b9aa02c9c274f5fd,
title = "Passive Transfer of A Germline-like Neutralizing Human Monoclonal Antibody Protects Transgenic Mice Against Lethal Middle East Respiratory Syndrome Coronavirus Infection",
abstract = "Middle East Respiratory Syndrome coronavirus (MERS-CoV) has repeatedly caused outbreaks in the Arabian Peninsula. To date, no approved medical countermeasures (MCM) are available to combat MERS-CoV infections. Several neutralizing human monoclonal antibodies (mAbs), including m336, a germline-like human mAb, have been chosen as promising MCM for MERS-CoV. However, their clinical development has been hindered by the lack of a robust animal model that recapitulate the morbidity and mortality of human infections. We assessed the prophylactic and therapeutic efficacy of m336 by using well-characterized transgenic mice shown to be highly sensitive to MERS-CoV infection and disease. We found that mice treated with m336 prior to or post lethal MERS-CoV challenging were fully protected, compared to control mice which sufferered from profound weight loss and uniform death within days after infection. Taken together, these results support further development of m336 and other human monoclonal antibodies as potential therapeutics for MERS-CoV infection.",
author = "Agrawal, {Anurodh Shankar} and Tianlei Ying and Xinrong Tao and Tania Garron and Abdullah Algaissi and Yanping Wang and Lili Wang and Bihung Peng and Shibo Jiang and Dimitrov, {Dimiter S.} and Chien-Te Tseng",
year = "2016",
month = "8",
day = "19",
doi = "10.1038/srep31629",
language = "English (US)",
volume = "6",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Passive Transfer of A Germline-like Neutralizing Human Monoclonal Antibody Protects Transgenic Mice Against Lethal Middle East Respiratory Syndrome Coronavirus Infection

AU - Agrawal, Anurodh Shankar

AU - Ying, Tianlei

AU - Tao, Xinrong

AU - Garron, Tania

AU - Algaissi, Abdullah

AU - Wang, Yanping

AU - Wang, Lili

AU - Peng, Bihung

AU - Jiang, Shibo

AU - Dimitrov, Dimiter S.

AU - Tseng, Chien-Te

PY - 2016/8/19

Y1 - 2016/8/19

N2 - Middle East Respiratory Syndrome coronavirus (MERS-CoV) has repeatedly caused outbreaks in the Arabian Peninsula. To date, no approved medical countermeasures (MCM) are available to combat MERS-CoV infections. Several neutralizing human monoclonal antibodies (mAbs), including m336, a germline-like human mAb, have been chosen as promising MCM for MERS-CoV. However, their clinical development has been hindered by the lack of a robust animal model that recapitulate the morbidity and mortality of human infections. We assessed the prophylactic and therapeutic efficacy of m336 by using well-characterized transgenic mice shown to be highly sensitive to MERS-CoV infection and disease. We found that mice treated with m336 prior to or post lethal MERS-CoV challenging were fully protected, compared to control mice which sufferered from profound weight loss and uniform death within days after infection. Taken together, these results support further development of m336 and other human monoclonal antibodies as potential therapeutics for MERS-CoV infection.

AB - Middle East Respiratory Syndrome coronavirus (MERS-CoV) has repeatedly caused outbreaks in the Arabian Peninsula. To date, no approved medical countermeasures (MCM) are available to combat MERS-CoV infections. Several neutralizing human monoclonal antibodies (mAbs), including m336, a germline-like human mAb, have been chosen as promising MCM for MERS-CoV. However, their clinical development has been hindered by the lack of a robust animal model that recapitulate the morbidity and mortality of human infections. We assessed the prophylactic and therapeutic efficacy of m336 by using well-characterized transgenic mice shown to be highly sensitive to MERS-CoV infection and disease. We found that mice treated with m336 prior to or post lethal MERS-CoV challenging were fully protected, compared to control mice which sufferered from profound weight loss and uniform death within days after infection. Taken together, these results support further development of m336 and other human monoclonal antibodies as potential therapeutics for MERS-CoV infection.

UR - http://www.scopus.com/inward/record.url?scp=84983334840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983334840&partnerID=8YFLogxK

U2 - 10.1038/srep31629

DO - 10.1038/srep31629

M3 - Article

VL - 6

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 31629

ER -